LPCAT3: The Key Player in MASH Progression to Hepatocellular Carcinoma

　　Untreated metabolic dysfunction-associated steatohepatitis(MASH)can progress to hepatocellular carcinoma(HCC).A groundbreaking study led by institutions including Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine has identified lysophosphatidylcholine acyltransferase 3(LPCAT3)as a central regulator in this deadly transition.LPCAT3 deficiency accelerates MASH to HCC,while its overexpression suppresses tumor development,highlighting its therapeutic potential.

　　1.LPCAT3 Deficiency:Fueling Disease Aggression

　　Mouse models fed a high-fat and high-cholesterol diet showed significantly reduced LPCAT3 expression in the liver.This deficiency exacerbated inflammation and fibrosis in MASH,accelerating the transition to HCC.LPCAT3 acts as a"guardian"of liver health;its absence disrupts cellular homeostasis and elevates cancer risk.

　　2.Mechanism:Mitochondrial Dysfunction Cascade

　　LPCAT3 deficiency triggers the Pdi(protein disulfide isomerase)-Ero1α(endoplasmic reticulum oxidoreductin 1α)pathway,causing accumulation of mitochondrial hydrogen peroxide(H₂O₂)and calcium ions(Ca²⁺),which impair oxidative phosphorylation.Concurrently,depletion of the essential phospholipid PC(18:2/18:2)disrupts cellular energy metabolism.Supplementing PC(18:2/18:2)reverses these abnormalities,indicating that LPCAT3 suppresses tumorigenesis by maintaining mitochondrial integrity.

　　3.LPCAT3 Overexpression:Halting Disease Progression

　　Liver-specific LPCAT3 overexpression in animal models significantly improved mitochondrial function,attenuated inflammation and fibrosis,and blocked MASH-to-HCC progression.This demonstrates LPCAT3's potential as a therapeutic target for preventing and treating MASH-related liver cancer.

　　Significance:This study elucidates,for the first time,how LPCAT3 regulates mitochondrial function through the Pdi-Ero1αaxis,unraveling the molecular mechanisms of MASH malignant transformation.Targeting LPCAT3 represents a promising strategy to combat liver cancer,paving the way for precision interventions.